Internal News Director's Notices Internal Pages Webmail

Technology Transfer

Total income (in thousands CZK), income per 1 employee according to FTE, and summary of applied results in the period 2007 – 2011


Parametr 2007 2008 2009 2010 2011
FTE* 147(247) 167(274) 182(289) 181(278) 187(292)
Income from national R&D funding 144,006 147,503 160,374 175,998 168,955
Income from international grants 16,133 14,299 13,885 7,780 14,916
Institutional funding 199,870 137,204 152,493 142,665 145,636
Contractual research and sale of R&D services 8,499 11,068 14,926 18,005 27,052
Total income 368,508 310,074 341,678 344,448 356,559
Total per 1 researcher** 2507(1492) 1856(1131) 1877(1182) 1903(1239) 1907(1221)

* Numbers of Institute employees in parentheses.
** Income per total number of the Institute employees (regardless of FTE) in parentheses

The Table shows that in 2011 the income from contractual research and sale of R&D services represented ca 8 % of the total institutional funding.

 

Applied results

Prototype 27 22 38 43 33
Utility model         3
Patent     3 1  

List of Utility Models

Hozák P, Šlouf M, Nebesářová J, Moša M, Krivjanská M: Assembly of mutually recognizable nanoparticles for multiple ultrastructural labeling.
Date of Model: 07.02.2011. Model Number: 21711. [ISVAV] [IPO]

Hozák P, Šloufová I, Šlouf M, Nebesářová J: Assembly of mutually microscopically recognizable nanoparticles with golden surface for simultaneous triple immunomarking.
Date of Model: 24.02.2011. Model Number: 21822. [ISVAV] [IPO]

Hozák P, Novotný F, Šlouf M, Nebesářová J: Assembly of three mutually microscopically recognizable nanoparticles with golden surface for simultaneous triple immunomarking.
Date of Model: 24.02.2011. Model Number: 21823. [ISVAV] [IPO]

List of Patents

Smetana K, Dvořánková B, Lacina L, Strnad H, Kolář M, Chovanec M, Plzák J, Čada Z, Vlček Č: Combination of monoclonal antibodies or their Fab fragments for use as drugs and pharmaceutical compositions containing these antibodies or fragments thereof.
Date of Patent: 17.03.2010. Patent Number: 301597. [ISVAV] [IPO]

Hejnar J, Šenigl F: Regulatory promoter/enhancer element protected from DNA methylatian and transcriptional silencing.
Date of Patent: 26.03.2009. Patent Number: 300377. [ISVAV] [IPO]

Král V, Bříza T, Kejík Z, Králová J, Poučková P: Use of multimodal systems for preparation of therapeutic and diagnostic tools for management of malignant diseases.
Date of Patent: 02.02.2009. Patent Number: 300197. [ISVAV] [IPO]

Novák P, Sedlák D, Bartůněk P, Kotora M: Estrogen receptor alpha and beta ligands, methods for their preparation, and pharmaceutical compositions containing them.
Date of Patent: 26.03.2009. Patent Number: 300376. [ISVAV]

 

Applied research with participation of IMG researchers (mostly in collaboration with biotech companies) possesses clear economic potential. In the past 15 years, the IMG employees founded seven spin-off biotech companies, which operate independently and develop dynamically. Detailed information on these companies is mentioned below:

AppGenics s.r.o. Focused on production of cRNA and cDNA labelled probes for in situ hybridization, development of novel vectors with desirable properties, preparation of recombinant proteins, cloning and gene engineering, and on advanced technologies for preparation of transgenic and knock-out animal models. The company is also familiar with embryonic stem cell technologies.
Apronex s.r.o.
http://www.apronex.cz/		 Focused on research, development and production of biologically active recombinant proteins.
Cellvia s.r.o. Focused on development of small molecule-based drugs; activities are still at the launching phase.
EXBIO Praha a.s.
http://www.exbio.cz/		 Focused on research, development and production of monoclonal antibodies and recombinant.
Proteix s.r.o.
http://www.proteix.cz/		 Focused on research, development and production recombinant proteins.
rEcoli s.r.o. Focused on production of recombinant proteins.
Top-Bio s.r.o.
http://www.top-bio.cz/		 Focused on development and production of reagents for DNA fragment amplification by polymerase chain reaction.

In the past 15 years, more than 150 commercially exploited hybridoma cell lines and plasmid constructs for preparation of recombinant proteins have been produced and transferred to implementation partners (Exbio, Apronex, Top-Bio) on contractual basis.

The total commercial turnover based on these products in the past 15 years was more than CZK 200 millions.

Selected results of cooperation with commercial sphere and other organizations obtained during implementation of IMG projects in the years 2010 and 2011

Utilization of nanofibre carriers to transport stem cells for medical purposes. Result obtained during implementation of project Biocompatible nanofibre scaffolds forming novel drug matrices for the application of biologically and pharmacologically active substances. Collaborating partners: company Elmarco s.r.o., Institute of Experimental Medicine AS CR, v. v. i., Institute of Macromolecular Chemistry AS CR, v. v. i.
Recombinant Strep-TRItag-TRAIL expression plasmid for selective precipitation of TRAIL-TRAIL-R complexes. Preparation and characterization of monoclonal antibody against cytoskeletal protein NFH. Preparation and characterization of monoclonal antibodies recognizing human protein Abraxas-1. Plasmids expressing recombinant proteins hAPP-IgG and hAPLP2-IgG. Preparation and characterization of human protein LGR5 and polyclonal antibodies recognizing human protein LGR5. Results obtained in implementing the project “Centre for Molecular and Cellular Immunology”. These results are applied in practice by companies Exbio Praha a.s. and Apronex, s.r.o. Collaborating partners: Institute of Microbiology AS CR, v. v. i., Faculty of Science, Charles University Prague; companies Exbio Praha a.s., Apronex s.r.o.
Preparation of monoclonal antibodies against proteins CLIC5a, LARGE and OPAL1. Results obtained in implementing the project “Centre for Molecular and Cellular Immunology”. These results are applied in practice by company Apronex s.r.o. Collaborating partners: 2nd Faculty of Medicine, Charles University Prague; company Apronex s.r.o.
Fifteen hybridoma cell lines prepared as part of the project “Structure and Disorders of the Cell Nucleus Nucleoskeleton – Identification and Diagnostics”. Collaborating partner: company KRD s.r.o.
Nanoparticles conjugated with antibodies of hybridoma cell lines 2E3-41, 3B6-3, 4C6-37, 5G3-51, 6B4-56, 6B4-57, 6D6-16 a 6D6-34, prepared as part of the project “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o.
Construction of nanofibre carriers with incorporated cyclosporin A and carrying stem cells for therapeutic purposes. Result obtained during implementation of project “Biocompatible Nanofibre Scaffolds Forming Novel Drug Matrices for the Application of Biologically and Pharmacologically Active Substances”. Collaborating partners: company Elmarco s.r.o., Institute of Experimental Medicine AS CR, v. v. i., Institute of Macromolecular Chemistry AS CR, v. v. i.
Novel universal qPCR mixes. Result obtained during implementation of project “Nano-PCR, Ultrasensitive Test for Detection of Specific Proteins in Body Fluids”. Collaborating partners: 3rd Faculty of Medicine, Charles University in Prague, Psychiatric Centre Prague, companies Vidia, s.r.o., Top-Bio s.r.o.
Novel method for establishment of low protein concentrations in complex biological fluids using nano-iPCR. Result obtained during implementation of project: “Nano-PCR, Ultrasensitive Test for Detection of Specific Proteins in Body Fluids”. Collaborating partners: 3rd Faculty of Medicine, Charles University in Prague, Psychiatric Centre Prague, companies Vidia, s.r.o., Top-Bio s.r.o.
Certified methodology – Qualitative proof of viral vaccine antigens. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company SEVAPHARMA a.s.
Monoclonal antibodies 2E3.H3.F2, 4C6.D12.D2, 5G3.E1.G9, 5G3.E5.A8 a 6B4.E9.B4 conjugated with golden rods. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o.
Monoclonal antibodies 2E3.H3.F2, 3B6.0.C7, 4C6.D12.D2, 5G3.E5.A8, 6B4.E9.B4, 6B4.E9.B6, 6B4.E9.B12 a6D6.F10.D12 conjugated with cubic palladium nanoparticles. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o.